Multicenter evaluation of the haemostatic activity of emicizumab in patients with severe haemophilia A

CONCLUSION: Using a modified TGA, this study showed that patients who experienced breakthrough bleeds while on emicizumab had a lower thrombin generating capacity compared to others with good clinical response to emicizumab.PMID:38583717 | DOI:10.1016/j.jtha.2024.03.022

Source: Thrombosis and Haemostasis - April 7, 2024 Category: Hematology Authors: Laurie Josset Alexandre Leuci Maissaa Janbain Ana ëlle De-Wreede Stephanie Desage Anne Lienhart Val érie Bin Doroth ée Lambert Xavier Delavenne Yesim Dargaud Source Type: research